As patents for biologics emerge on the marketplace, what will be their role within the cancer community? Will biosimilars provide alternatives for cancer treatment? In addition to alternatives, what information and education is needed for stakeholders to make informed choices about the cancer treatments? During the 2018 annual American Society of Clinical Oncology (ASCO) meeting, I joined Gary Lyman of the Fred Hutchinson Cancer Research in a roundtable discussion hosted by Steve Clemons to discuss the issues. At the time of this live panel that was attended by over 100 ASCO registrants, I was a VP and CMO of Cardinal Health Specialty Solutions. The panel discussion was sponsored by “The Atlantic”. Grounded in the 160-year legacy of the magazine, AtlanticLIVE brings the unparalleled journalism of The Atlantic to life through singular event experiences, on stage and off.
